Bradicardia sinusal sintomática tras inicio de octreotide subcutánea

Tejedor, Manuel Cruz; Sánchez, Andrés López; Bellido, B. Morató; Gil, Inês; Sanz, J.E. Guerrero

doi:10.1016/j.medin.2010.12.005

Cited by 3 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although infrequent, bradycardia associated with octreotide has been reported in various clinical settings. [2][3][4][5][6][7][8] McCormick et al 7 described a significant decrease in pulse rate and cardiac output and increase in systemic vascular resistance immediately after an octreotide bolus. Tuncer et al 8 described atropine-responsive bradycardia, complete heart block, and hypotension on the 60th hour of octreotide infusion, with persistence of the heart block (despite correction of bradycardia) until 6 days after discontinuation.…”

Section: Discussionmentioning

confidence: 99%

Octreotide-induced asystolic events in an intensive care unit patient with gastrointestinal bleeding

2012

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Octreotide-induced asystolic events in an intensive care unit patient with gastrointestinal bleeding

2012

View full text Add to dashboard Cite

Systemic Octreotide Therapy in Prevention of Gastrointestinal Bleeds Related to Arteriovenous Malformations and Obscure Etiology in Atrial Fibrillation

Vuddanda

Jazayeri

Turagam

et al. 2017

JACC: Clinical Electrophysiology

View full text Add to dashboard Cite

show abstract

Medical Management of Inoperable Malignant Bowel Obstruction

et al. 2020

View full text Add to dashboard Cite

Objective: To review medical management of inoperable malignant bowel obstruction. Data Sources: A literature review using PubMed and MEDLINE databases searching malignant bowel obstruction, etiology, types, pathophysiology, medical, antisecretory, anti-inflammatory, antiemetic drugs, analgesics, promotion of emptying, prevention of infection, anticholinergics, somatostatin analogs, gastric antisecretory drugs, prokinetic agents, glucocorticoid, opioid analgesics, antibiotics, enema, and adverse effects. Study Selection and Data Extraction: Randomized or observational studies, cohorts, case reports, or reviews written in English between 1983 and November 2020 were evaluated. Data Synthesis: Malignant bowel obstruction (MBO) commonly occurs in patients with advanced or recurrent malignancies and severely affects the quality of life and survival of patients. Its management remains complex and variable. Medical management is the cornerstone of MBO treatment, with the goal of reducing distressing symptoms and optimizing quality of life. Until now, there has been neither a standard clinical approach nor registered medications to treat patients with inoperable MBO. Relevance to Patient Care and Clinical Practice: This review provides information on the etiology, type and pathophysiology, and medical treatment of MBO and related adverse reactions of the drugs commonly used, which can greatly assist clinicians in making clinical decisions when treating MBO. Conclusions: Published research shows that medical management of MBO mainly consists of antisecretory, anti-inflammatory strategies, controlling vomiting and pain, promoting emptying, preventing infection, and combination therapy. Being knowledgeable about the most current treatment options, the related adverse effects, and the evidence supporting different practices is critical for clinicians to provide individualized medical therapy for MBO patients.

show abstract

Bradicardia sinusal sintomática tras inicio de octreotide subcutánea

Cited by 3 publications

References 10 publications

Octreotide-induced asystolic events in an intensive care unit patient with gastrointestinal bleeding

Octreotide-induced asystolic events in an intensive care unit patient with gastrointestinal bleeding

Systemic Octreotide Therapy in Prevention of Gastrointestinal Bleeds Related to Arteriovenous Malformations and Obscure Etiology in Atrial Fibrillation

Medical Management of Inoperable Malignant Bowel Obstruction

Contact Info

Product

Resources

About